Thyrocare Technologies Limited announced the approval of unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company also approved an amendment to the “Code of Conduct to Regulate, Monitor, and Report Trading by Designated Persons and their Immediate Relatives” (PIT Code). The board meeting concluded at 4:05 P.M.
Financial Results Approved
The Board of Directors has given the green light to the unaudited standalone and consolidated financial results for the quarter and nine months which ended on December 31, 2025. Along with the approval, the Limited Review Report for the mentioned periods was also approved. Copies of the Standalone and Consolidated unaudited financial results along with the Limited Review Reports are included as Annexure A.
Amendment to Trading Code
An amendment to the “Code of Conduct to Regulate, Monitor, and Report Trading by Designated Persons and their Immediate Relatives” (PIT Code) has been approved by the Board. The amended PIT Code is included as Annexure B and can be found on the company’s website.
Financial Performance Highlights
Key figures from the unaudited standalone financial results for the quarter ended December 31, 2025 (Q3) compared to September 30, 2025 (Q2) are as follows:
- Total income: ₹185.91 crores (Q3) compared to ₹204.51 crores (Q2).
- Profit before exceptional items and tax: ₹42.59 crores (Q3) compared to ₹60.89 crores (Q2).
- Profit for the period: ₹26.15 crores (Q3) compared to ₹43.03 crores (Q2).
Other Key Updates
The board meeting commenced at 3:30 P.M. and concluded at 4:05 P.M. on January 28, 2026.
Source: BSE
